INSERM (Institut National de la Sante et de la Recherche Medicale;Centre National de la Recherche Scientifique (CNRS);Association Institut de Myologie;Sorbonne Universite
发明人:
Nicolas VIGNIER,Mathias MERICSKAY,Zhenlin LI,Antoine MUCHIR,Gisele BONNE,Nicolas DIGUET
申请号：
US16313332
公开号：
US20190350955A1
申请日:
2017.06.29
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to methods and pharmaceutical compositions for the treatment of cardiomyopathies. The inventors showed that the nicotinamide riboside kinase Nmrk2 gene involved in NAD+ biosynthetic pathway is strongly induced in the heart of the mouse models of dilated cardiomyopathy and that Nmrk2 is an AMPK and PPARα responsive gene. They also showed that the NMRK enzymes substrate nicotinamide riboside supplementation in food markedly improves cardiac functions and reduces eccentric remodeling. The inventors demonstrated that both the NMRK1 and NMRK2 protein are expressed in the human healthy heart, that NMRK2 protein level is increased in human failing hearts as it is the case in mouse failing hearts in several models of heart failure and cardiomyopathies. In particular, the present invention relates to nicotinamide riboside for use in the treatment of cardiomyopathy in a human subject in need thereof.
